LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression
Metrics: PDF 1052 views | HTML 1588 views | ?
Yang Du1,*, Xiao-Dong Weng1,*, Lei Wang1,*, Xiu-Heng Liu1, Heng-Cheng Zhu1, Jia Guo1, Jin-Zhuo Ning1 and Cheng-Cheng Xiao1
1Department of Urology, Ren’min Hospital of Wuhan University, Wuhan, Hubei 430000, China
*These authors have contributed equally to this work
Xiu-Heng Liu, email: firstname.lastname@example.org
Heng-Cheng Zhu, email: email@example.com
Keywords: prostate cancer, long non-coding RNA, XIST, miR-23a, RKIP
Received: June 29, 2017 Accepted: August 27, 2017 Published: October 10, 2017
Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism of XIST in prostate cancer remains unclear. In the current study, we found that XIST was down-regulated in prostate cancer specimens and cell lines. Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients. In gain and loss of function assays, we confirmed that XIST suppressed cellular proliferation and metastasis in prostate cancer both in vitro and in vivo. Furthermore, we found that XIST negatively regulates the expression of miR-23a and subsequently promotes RKIP expression at post-transcriptional level. Consequently, we investigated the correlation between XIST and miR-23a, and identified miR-23a as a direct target of XIST. In addition, over-expression of miR-23a efficiently abrogated the up-regulation of RKIP induced by XIST, suggesting that XIST positively regulates the expression of RKIP by competitively binding to miR-23a. Taken together, our study indicated that lncRNA XIST acts as a tumor suppressor in prostate cancer, and this regulatory effect of XIST will shed new light on epigenetic diagnostics and therapeutics in prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.